Althea has launched a new range of 20ml full-spectrum cannabis oil products in a bid to increase uptake by price-sensitive patients.

The products carry the same trade names, and utilise the same formulations, as Althea’s existing 50ml and 100ml products, but the 20ml size is designed to promote flexibility for patients, especially those just starting treatment or suffering from intermittent illnesses.

Althea said the smaller unit size allows new patients to trial the medication over the recommended 2 or 3-week titration period and then determine if it is beneficial for them in conjunction with their healthcare professional.

josh fegan
Althea CEO Joshua Fegan: price remains a challenge for potential patients

Once the patient has experienced a positive outcome from their medication, it is anticipated they will transition to the more economical (on a price per ml basis) larger-sized bottle.

The expanded product portfolio aims to provide price-sensitive patients with a lower entry point, thereby increasing patient acquisition. The Althea ‘flexi’ 20ml cannabis oil range is also expected to attract new prescribers and create incremental sales for the business.

Althea CEO Joshua Fegan said: “We understand that price remains a challenge for many potential new patients that want to trial medicinal cannabis for their conditions.

“We believe the launch of the new Althea ‘flexi’ 20ml cannabis oil range will be a great way to provide more access to patients via trial-size products.”

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment